ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
ProQR Announces Third Quarter 2024 Operating and Financial Results
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $14.00 price target on the stock, up previously from $6.00.
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement [Yahoo! Finance]
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement